A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Type of Cancer
Gynecologic

Site
Hackensack

Sponsor
Abbvie

Protocol Number
M13-694 (GOG-3005)

To Learn More Call
201-510-0910